2653-16-9

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-N-methyl-N-(4-nitrophenyl)acetamide is used as a reactant/reagent for the synthetic preparation of oxindole derivatives. These derivatives have been identified as inhibitors of tyrosine kinase, which are enzymes that play a crucial role in cell signaling and are often overactive in cancer cells. By inhibiting tyrosine kinase, these oxindole derivatives can potentially help in the development of targeted therapies for cancer treatment.

InChI:InChI=1/C9H9ClN2O3/c1-11(9(13)6-10)7-2-4-8(5-3-7)12(14)15/h2-5H,6H2,1H3

Upstream product

• 79-04-9 chloroacetyl chloride 
• 100-15-2 N-methyl(p-nitroaniline) 
• 4015-58-1 monochloroacetic acid anhydride 
• 541-88-8 Chloroacetic anhydride 
• 586-78-7 para-nitrophenyl bromide 
• 100-01-6 4-nitro-aniline 
• 77-78-1 dimethyl sulfate 
• 17329-87-2 2-chloro-N-(4-nitro-phenyl)-acetamide 
• 67-68-5 dimethyl sulfoxide 

Downstream Products

• 20870-89-7 1-methyl-5-nitro-1,3-dihydro-indol-2-one 
• 855860-75-2 N-(4-aminophenyl)-2-chloro-N-methylacetamide 
• 262368-30-9 N-[(4-methyl-piperazin-1-yl)methylcarbonyl]-N-methyl-p-phenylendiamine 
• 98589-93-6 1-methyl-6-nitro-1,2-dihydroquinoxalin-2-one 
• 1448363-12-9 2-azido-N-methyl-N-(4-nitrophenyl)acetamide 
• 656247-17-5 nintedanib 

Relevant academic research and scientific papers

Indolone derivative and pharmaceutical application thereof

The invention provides an indolone derivative and pharmaceutical application thereof. The structure of the indolone derivative is shown as a formula (A). Experimental results show that the compound provided by the invention has obviously improved pharmacokinetic properties than BIBF1120, has excellent inhibition effects on VEGFR, FGFR and PDGFR, can be used as a VEGFR, FGFR and/or PDGFR inhibitor,an angiogenesis inhibitor and a drug for preventing and/or treating various tumors including pharyngeal squamous cell carcinoma, and has a wide application prospect.

INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring C, X1, X2, L1, R1, R2, R3, R4, R5, R6, R7, m and n are as defined herein, which are useful as MAP4K1 inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by MAP4K1.

Novel synthesis method of nilotinib intermediate 2-chloro -N- methyl -N-(4- nitrophenyl) acetamide (by machine translation)

The method sequentially comprises the following steps, generating chlorine - 2 - N N-methyl -) N N N N. N (methyl - N N N N N- methyl-N,(N-)-nitrophenyl 2 - acetamide) in, a brand-new synthetic route in a brand-new synthesis route. 2 - The present invention, provides a) brand-new synthesis, route of compound chloride - N, N-methyl-N-(N-N-(N-(, N-(N, N,(N-(N-N-(N-(N-N-(N-(N-(N-N-(N-(N-N-(N. (by machine translation)

INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE

The present disclosure relates to indolinone compounds, compositions, and methods for the inhibition of maternal embryonic leucine zipper kinase (MELK). The present disclosure further relates to indolinone compounds, compositions, and methods for the treatment or prevention of a cancer (for example, triple negative breast cancer).

Method for preparing Nintedanib,I intermediate through one-pot method

The invention relates to a method for preparing Nintedanib,I key intermediate N-(4-aminophenyl)-N-methyl-2-(4-methyl piperazine-1-group)acetamide through a one-pot method. The method comprises the steps that according to the technical scheme, N-methyl-4-nitroaniline is dissolved in an aqueous solution of an organic solvent and alkali, mixing is carried out, then chloroacetyl chloride or bromoacetyl bromide is dropwise added, and a first-stage reaction is carried out for 0.1-3 hours at the temperature of 0-70 DEG C; a water layer is removed, N-methyl piperazine is added, a second-stage reactionis carried out, and reacting is carried out for 2-10 hours at the temperature of 0-75 DEG C; then a reducing reagent is added, a third-stage reaction is carried out for 8-36 hours at the temperatureof 0-75 DEG C and the pressure of 15-100 psi. After the reaction is finished, filtering is carried out to remove the reducing reagent, the reaction liquid is condensed, a reverse phase solvent is added, crystallization is carried out, and the Nintedanib,I key intermediate N-(4-aminophenyl)-N-methyl-2-(4-methyl piperazine-1-group)acetamide (formula B) is obtained. According to the preparation method, the raw materials are easy to obtain, the process is simple, and the method is economical, environmentally friendly and suitable for industrial production.

Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth

Despite recent advances in molecularly directed therapy, triple negative breast cancer (TNBC) remains one of the most aggressive forms of breast cancer, still without a suitable target for specific inhibitors. Maternal embryonic leucine zipper kinase (MELK) is highly expressed in TNBC, where level of overexpression correlates with poor prognosis and an aggressive disease course. Herein, we describe the discovery through targeted kinase inhibitor library screening, and structure-guided design of a series of ATP-competitive indolinone derivatives with subnanomolar inhibition constants towards MELK. The most potent compound, 17, inhibits the expression of the anti-apoptotic protein Mcl-1 and proliferation of TNBC cells exhibiting selectivity for cells expressing high levels of MELK. These studies suggest that further elaboration of 17 will furnish MELK-selective inhibitors with potential for development in preclinical models of TNBC and other cancers.

Nintedanib impurity and preparation method and application thereof

The invention relates to a nintedanib impurity represented by the formula VI and a preparation method thereof. The preparation method comprises that with N-methyl-4-nitroaniline as a starting material, the compound is obtained through the steps of acylation, substitution, acylation, substitution, reduction, substitution reactions and the like. The compound and an intermediate compound represented by the formula V can be used as reference substances for detection of nintedanib raw materials and preparation related substances.

Indole ketone compound or its derivatives and their use

The present invention relates to indolone compounds shown by general formula (a) or derivatives thereof, and uses thereof. The technical problem solved by the present invention is to provide indolone compounds or derivatives thereof, and uses thereof. The present invention uses a deuterium-enriched indolone compound obtained from a deuterium-substituted indolone compound. The above-mentioned indolone compounds can simultaneously effect on three key receptor families involved in the process of blood vessel formation, i.e., vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), and platelet-derived growth factor receptor (PDGFR), and inhibit the formation of blood vessel, thereby achieving the effect of treating cancers. The above-mentioned deuterium-substituted indolone compounds or derivatives thereof have the advantage of high efficiency as medicaments.

OXINDOLE INHIBITORS OF TYROSINE KINASE

The present invention relates to new oxindole inhibitors of tyrosine kinase, pharmaceutical compositions thereof, and methods of use thereof.

Design, synthesis and biological evaluation of deuterated nintedanib for improving pharmacokinetic properties

Nintedanib is a novel triple angiokinase inhibitor that inhibits three growth factors simultaneously. Deuterated derivatives of nintedanib at certain metabolically active sites were prepared and evaluated in vitro and in vivo. In particular, deuterated compound SKLB-C2202 had significantly improved pharmacokinetic properties compared with nintedanib. These efforts lay the foundation for further investigating the druggability of SKLB-C2202. Deuterated derivatives of nintedanib at certain metabolically active sites were prepared and evaluated in vitro and in vivo. Deuterated compound SKLB-C2202 had significantly improved pharmacokinetic properties compared with nintedanib. Further research is underway.